 1. Combination therapy with pembrolizumab KEYTRUDA, anti-PD-1 - for patients with PD-L1 or PD-L2 positive tumors defined as at least 1 of tumor cells on biopsy or archival material, or 1 of circulating tumor cells, staining positive for PD-L1 or PD-L2. 